Black Diamond Therapeutics (BDTX)
(Delayed Data from NSDQ)
$4.69 USD
0.00 (0.00%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $4.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Black Diamond Therapeutics, Inc. [BDTX]
Reports for Purchase
Showing records 61 - 80 ( 89 total )
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Q2 Financials; BDTX-189 RP2D Selected; Ph 2 Set to Initiate
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
ASCO 2021 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Pushing Forward Through Diversity; Ph 1 Dataset Encouraging
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX-189 Shows Improved Safety and Initial Anti-Tumor Activity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Q1 Financials; First Look at BDTX-189 Ahead at ASCO
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Takeaways from 2021 AACR Virtual Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Competitive Landscape Updates from AACR; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
4Q20 Earnings; Preliminary BDTX-189 Data Expected 1H:2021
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Partial Clinical Hold Non-Impactful, In Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX Presents Preclinical Data for BRAF and FGFR 2/3 MasterKey Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Intriguing Preclinical BRAF and FGFR Programs Could Drive Upside to Our Valuation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Biliary Cancer Data Further Supports Tumor Agnostic Strategy
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R